Satsuma Pharmaceuticals Inc (STSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2013 | 06-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 71,487 | 50,439 | 22,678 | 385,721 | 364,775 |
| Depreciation Amortization | 32,452 | 21,740 | 10,692 | 45,843 | 33,871 |
| Income taxes - deferred | N/A | N/A | N/A | -291,880 | N/A |
| Other Working Capital | 232,660 | 99,116 | 106,460 | -321,937 | -179,657 |
| Loans | 271,472 | 153,727 | 155,489 | -308,844 | -157,253 |
| Other Operating Activity | -280,852 | -164,853 | -165,021 | 364,598 | -110,998 |
| Operating Cash Flow | $327,219 | $160,169 | $130,298 | $-126,499 | $-49,262 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -14,568 | -9,125 | -5,537 | -9,853 | -14,144 |
| Net Acquisitions | -115,768 | -115,768 | 6,877 | 121,098 | 121,098 |
| Purchase Of Investment | -322,965 | -280,490 | -76,590 | -291,583 | -291,583 |
| Sale Of Investment | 281,305 | 201,999 | 108,267 | 1,513,571 | 992,881 |
| Net Loans | -620,563 | -406,604 | -127,325 | -361,096 | -242,084 |
| Other Investing Activity | 53,162 | 32,566 | 23,439 | 82,791 | 58,658 |
| Investing Cash Flow | $-739,397 | $-577,422 | $-70,869 | $1,054,928 | $624,826 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | -8,942 | -5,801 | -18,896 | N/A |
| Debt Issued | 1,385,000 | 1,060,000 | 225,000 | 545,000 | 50,000 |
| Debt Repayment | -963,472 | -468,440 | -290,054 | -345,210 | -300,157 |
| Common Stock Issued | 868 | 413 | 413 | 661 | 572 |
| Dividend Paid | -46,727 | -12,468 | N/A | -49,743 | -9,322 |
| Other Financing Activity | -52,198 | -50,000 | -50,000 | -485,342 | -113,216 |
| Financing Cash Flow | $455,328 | $426,437 | $-76,943 | $-1,099,150 | $-813,950 |
| Beginning Cash Position | 299,878 | 299,878 | 299,878 | 470,599 | 470,599 |
| End Cash Position | 343,028 | 309,062 | 282,364 | 299,878 | 232,213 |
| Net Cash Flow | $43,150 | $9,184 | $-17,514 | $-170,721 | $-238,386 |
| Free Cash Flow | |||||
| Operating Cash Flow | 327,219 | 160,169 | 130,298 | -126,499 | -49,262 |
| Capital Expenditure | -14,568 | -9,125 | -5,537 | N/A | -14,144 |
| Free Cash Flow | 312,651 | 151,044 | 124,761 | -126,499 | -63,406 |